KROS
Keros Therapeutics, Inc. Common Stock
Nasdaq · usd
Keros Therapeutics, Inc. Common Stock (KROS) trades at $11.08 (-2.72%) as of 4:25:24 PM EST on Nov 20, 2026, -2.38% over the past month. Market cap is $223.52M, with 7.1 days to cover in short interest.
Stock performance
How Keros Therapeutics, Inc. Common Stock (KROS) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.72%
- 1W
- +7.57%
- 1M
- -2.38%
- YTD
- -45.58%
- 1Y
- -36.29%
- 52-wk range
- $8.98 – $22.55
Key statistics
Today's trading snapshot for KROS: day range, open, previous close, volume and market cap.
- Day range
- $10.95 – $11.59
- Open
- $11.18
- Prev close
- $11.39
- Volume
- 208.69K
- Market cap
- $223.52M
- Shares out
- 19.62M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Keros Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 5.48
- P/B
- 0.80
- P/FCF
- —
- ROE
- -22.1%
- ROA
- -20.1%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 19, 2026
8-K filings
Material corporate events Keros Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Share repurchase programNov 16, 2026
On November 16, 2026, Keros Therapeutics, Inc. ... issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company's common stock.
- Quarterly earningsNov 5, 2026
On November 5, 2026, Keros Therapeutics, Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the quarter ended September 30, 2026.
- Investor presentationNov 5, 2026
On November 5, 2026, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.
- Licensing agreementSep 29, 2026
The Company will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda Pharmaceuticals U.S.A., Inc.
- Guidance issuance or updateSep 8, 2026
Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of June 30, 2026, after giving effect to (i) the $20 million development milestone received under the license agreement with Takeda and (ii) the Stock Repurchase, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2028.
KROS short interest
How heavily KROS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.1
- Short interest
- 1.09M
- Avg volume
- 153.86K
As of · reported to FINRA twice monthly.
KROS news
The latest news and headlines about Keros Therapeutics, Inc. Common Stock (KROS).
- What Makes Keros Therapeutics (KROS) a New Strong Buy StockpositiveZacks Investment Research· Nov 19, 2026
- Best Momentum Stocks to Buy for November 19thpositiveZacks Investment Research· Nov 19, 2026
- Wall Street Analysts Predict a 57.17% Upside in Keros Therapeutics (KROS): Here's What You Should KnowpositiveZacks Investment Research· Nov 19, 2026
- New Strong Buy Stocks for November 19thpositiveZacks Investment Research· Nov 19, 2026
- Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass EstimatesneutralZacks Investment Research· Nov 5, 2026
Frequently asked questions
What is the Keros Therapeutics, Inc. Common Stock (KROS) stock price today?
Keros Therapeutics, Inc. Common Stock (KROS) is trading at $11.08 (-2.72% on the day) as of 4:25:24 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Keros Therapeutics, Inc. Common Stock?
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs.
What is the short interest in KROS?
As of Oct 30, 2026, KROS has 1.09M shares short and 7.1 days to cover.
What exchange is KROS listed on?
Keros Therapeutics, Inc. Common Stock (KROS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of KROS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a KROS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.